Aclaris Therapeutics (ACRS) Receiving Positive Media Coverage, Analysis Shows

Media coverage about Aclaris Therapeutics (NASDAQ:ACRS) has been trending positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.1692985169313 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s analysis:

A number of analysts recently commented on ACRS shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 target price on shares of Aclaris Therapeutics in a research note on Monday, September 18th. ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research note on Tuesday. Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 target price on shares of Aclaris Therapeutics in a research note on Monday, July 31st. Finally, JMP Securities reiterated an “outperform” rating and issued a $39.00 target price on shares of Aclaris Therapeutics in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $39.20.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12.

In other news, Director Andrew N. Schiff acquired 108,601 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average cost of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Aclaris Therapeutics (ACRS) Receiving Positive Media Coverage, Analysis Shows” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/10/12/aclaris-therapeutics-acrs-receiving-positive-media-coverage-analysis-shows.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Insider Buying and Selling by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply